BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I Populations
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
Kobo Resources Advances Kossou Toward Resource Definition While Expanding Gold Mineralisation Beyond Known Structures
Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation
